Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

NCT07825857 on ClinicalTrials.gov · last registry update 2026-09-23

An unusually large phase 2: 228 participants, more than double the 110 typical for the stage. Due to report 1 July 2031, alongside 3 other tracked readouts that quarter. Primary outcome, as filed: Treatment response. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Texas Southwestern Medical Center
Sponsor type: Other
Enrollment: 228
Started: 2026-10-01
Primary completion: 2031-07-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-17	First seen in registry	Registered as NOT_YET_RECRUITING, P2

Primary outcome

Treatment response

Conditions studied

Methamphetamine Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.